The process of metastasisation for breast cancer

European Journal of Cancer

Volumn 39, Issue 12, 2003, Pages 1794-1806

  Engel, J ^a   Eckel, R ^a   Kerr, J ^a   Schmidt, M ^a   Furstenberger G ^b   Richter, R ^b   Sauer, H ^a   Senn, H J ^b   Holzel D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Tumor Center ZeTuP   (Switzerland)

Author keywords

Breast cancer; Epidemiology; Local recurrence; Metastasis; Tumour registry

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURVIVAL; CORRELATION ANALYSIS; EARLY DIAGNOSIS; FEMALE; GERMANY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0041346024     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00422-2     Document Type: Article

References (83)

1. Overgaard M., Hansen P.S., Overgaard J.et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 337:1997;949-955.
2. Ragaz J., Jackson S.M., Le N.et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 337:1997;956-962.
3. Hellman S. Stopping metastases at their source. N. Engl. J. Med. 337:1997;996-997.
4. Arriagada R., Rutqvist L.E., Mattsson A., Kramar A., Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J. Clin. Oncol. 13:1995;2869-2878.
5. Bartelink H., Horiot J.-C., Poortmans P.et al. Group ftEOfRaToCRaBC. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. New Engl. J. Med. 345:2001;1378.
6. Evans R.A. Radiotherapy and chemotherapy in high-risk breast cancer. N. Engl. J. Med. 338:1998;331. [discussion 331-332].
7. Fortin A., Larochelle M., Laverdiere J., Lavertu S., Tremblay D. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J. Clin. Oncol. 17:1999;101-109.
8. Gelman R., Harris J.R. Editorial comment on "the link between local recurrence and distant metastasis in human breast cancer" by Serge Koscielny and Maurice Tubiana. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;7-9.
9. Kemperman H., Borger J., Hart A., Peterse H., Bartelink H., van Dongen J. Prognostic factors for survival after breast conserving therapy for stage I and II breast cancer. The role of local recurrence. Eur. J. Cancer. 31A:1995;690-698.
10. Veronesi U., Marubini E., Del Vecchio M.et al. Local recurrences and distant metastases after conservative breast cancer treatments. partly independent events J. Natl. Cancer Inst. 87:1995;19-27.
11. Demicheli R., Retsky M.W., Swartzendruber D.E., Bonadonna G. Proposal for a new model of breast cancer metastatic development. Ann. Oncol. 8:1997;1075-1080.
12. Karrison T.G., Ferguson D.J., Meier P. Dormancy of mammary carcinoma after mastectomy. J. Natl. Cancer Inst. 91:1999;80-85.
13. Halsted W. The results of operations for the cure of the cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. Arch. Surg. 20:1894;497.
14. Fisher B. The surgical dilemma in the primary therapy of invasive breast cancer. a critical appraisal Curr. Probl. Surg. 33:1970;1.
15. Hellman S., Harris J.R. The appropriate breast cancer paradigm. Cancer Res. 47:1987;339-342.
16. Jatoi I. Breast cancer. a systemic or local disease? Am. J. Clin. Oncol. 20:1997;536-539.
17. Koscielny S., Tubiana M. The link between local recurrence and distant metastases in human breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;11-24.
18. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. experience from a large study with long-term follow-up Histopathology. 19:1991;403-410.
19. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 38:1982;933-942.
20. Michaelson J.S., Silverstein M., Wyatt J.et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer. 95:2002;713-723.
21. Kamby C., Sengelov L. Survival and pattern of failure following locoregional recurrence of breast cancer. Clin. Oncol. R. Coll. Radiol. 11:1999;156-163.
22. Leivonen M.K., Kalima T.V. Prognostic factors associated with survival after breast cancer recurrence. Acta Oncol. 30:1991;583-586.
23. Shapiro S., Goldberg J.D., Hutchison G.B. Lead time in breast cancer detection and implications for periodicity of screening. Am. J. Epidemiol. 100:1974;357-366.
24. Engel J., Baumert J., Sauer H., Hölzel D. Qualitätssicherung in der Onkologie am Beispiel des Mammakarzinoms der Feldstudie München. Onkologe. 7:2001;307-320.
25. Peer P.G., van Dijck J.A., Hendriks J.H., Holland R., Verbeek A.L. Age-dependent growth rate of primary breast cancer. Cancer. 71:1993;3547-3551.
26. Hart D., Shochat E., Agur Z. The growth law of primary breast cancer as inferred from mammography screening trials data. Br. J. Cancer. 78:1998;382-387.
27. Tabar L., Vitak B., Tony H.H., Yen M.F., Duffy S.W., Smith R.A. Beyond randomized controlled trials. organized mammographic screening substantially reduces breast carcinoma mortality Cancer. 91:2001;1724-1731.
28. Woodman C.B., Threlfall A.G., Boggis C.R.M., Prior P. Is the three year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme's north western region. Br. Med. J. 310:1995;224-226.
29. Perry N., Broeders M., deWolf C., Törnberg S. European Guidelines for Quality Assurance in Mammography Screening. 3rd edn. 2001;European Commission, Brussels.
30. Hölzel D., Engel J., Schmidt M., Sauer H. Modell zur primären Metastasierung beim Mammakarzinom und dessen klinische Bedeutung. Strahlenther. Onkol. 177:2001;10-24.
31. Blanco G., Holli K., Heikkinen M., Kallioniemi O.P., Taskinen P. Prognostic factors in recurrent breast cancer. relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading Br. J. Cancer. 62:1990;142-146.
32. Vogel C.L., Azevedo S., Hilsenbeck S., East D.R., Ayub J. Survival after first recurrence of breast cancer. The Miami experience. Cancer. 70:1992;129-135.
33. Salvadori B. Local recurrences after breast-conserving treatment. an open problem Semin. Surg. Oncol. 12:1996;46-52.
34. Schnitt S.J., Abner A., Gelman R.et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer. 74:1994;1746-1751.
35. Kurtz J.M., Amalric R., Brandone H.et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer. 63:1989;1912-1917.
36. Recht A., Hayes D.F., Eberlein T.J., Sadowsky L. Local-reginal recurrence after mastectomy or breast conserving therapy. Dis. Breast. 1996;649-667.
37. Bartelink H., Borger J.H., van Dongen J.A., Peterse J.L. The impact of tumor size and histology on local control after breast-conserving therapy. Radiother. Oncol. 11:1988;297-303.
38. Reid S.E., Murthy M.S., Kaufman M., Scanlon E.F. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br. J. Surg. 83:1996;1037-1046.
39. Touboul E., Buffat L., Belkacemi Y.et al. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;25-38.
40. Voogd A.C., Peterse J.L., Crommelin M.A.et al. Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST). Eur. J. Cancer. 35:1999;1828-1837.
41. Willner J., Kiricuta I.C., Kölbl O. Locoregional recurrence of breast cancer following mastectomy. always a fatal event? Results of univariate and multivariate analysis Int. J. Radiat. Oncol. Biol. Phys. 37:1997;853-863.
42. Macmillan R.D., Purushotham A.D., George W.D.et al. Local recurrence after breast-conserving surgery for breast cancer. Br. J. Surg. 83:1996;149-155.
43. Pierce L.J., Lichter A.S. Defining the role of post-mastectomy radiotherapy. the new evidence Oncology (Huntingt.). 10:1996;991-1002. [discussion 1006-1007, 1011].
44. Voogd A., Nielsen M., Peterse J., Bilchert-Toft M.et al. Group DBCC, Cancer BCCGotEOfRaTo. Differences in risk factors for local recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer. pooled results of two large European randomized trials J. Clin. Oncol. 19:2001;1688-1697.
45. Fowble B., Solin L.J., Schultz D.J., Rubenstein J., Goodman R.L. Breast recurrence following conservative surgery and radiation. patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment Int. J. Radiat. Oncol. Biol. Phys. 19:1990;833-842.
46. Levitt S.H. The importance of locoregional control in the treatment of breast cancer and its impact on survival. Cancer. 74:1994;1840-1846.
47. Haffty B.G., Fischer D., Beinfield M., McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int. J. Radiat. Oncol. Biol. Phys. 21:1991;293-298.
48. Halverson K.J., Perez C.A., Kuske R.R., Garcia D.M., Simpson J.R., Fineberg B. Survival following locoregional recurrence of breast cancer. univariate and multivariate analysis Int. J. Radiat. Oncol. Biol. Phys. 23:1992;285-291.
49. Recht A., Schnitt S.J., Connolly J.L.et al. Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;3-9.
50. Cowen D., Jacquemier J., Houvenaeghel G.et al. Local and distant recurrence after conservative management of "very low-risk" breast cancer are dependent events. a 10-year follow-up Int. J. Radiat. Oncol. Biol. Phys. 41:1998;801-807.
51. Cuzick J., Stewart H., Rutqvist L.et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 12:1994;447-453.
52. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer. an overview of the randomised trials Lancet. 355:2000;1757-1770.
53. Fisher B., Anderson S., Bryant J.et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med. 347:2002;1233-1241.
54. Veronesi U., Cascinelli N., Mariani L.et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 347:2002;1227-1232.
55. Overgaard M., Jensen M.B., Overgaard J.et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen. Danish Breast Cancer Cooperative Group DBCG 82c randomised trial Lancet. 353:1999;1641-1648.
56. Wolberg W.H., Robins H.I. Radiotherapy and chemotherapy in high-risk breast cancer. N. Engl. J. Med. 338:1998;329-330. [discussion 331-332].
57. Mokbel K., Reed M.J. Benefits of post-mastectomy radiotherapy. Lancet. 351:1998;219.
58. Fisher B.J., Perera F.E., Cooke A.L.et al. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone. patterns of recurrence Int. J. Radiat. Oncol. Biol. Phys. 38:1997;541-550.
59. Vicini F.A., Horwitz E.M., Lacerna M.D.et al. The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breast-conserving therapy. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;1069-1076.
60. Yarnold J. Benefits of post-mastectomy radiotherapy. Lancet. 350:1997;1415-1416.
61. Danforth D.N. Jr., Findlay P.A., McDonald H.D.et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J. Clin. Oncol. 4:1986;655-662.
62. Kiricuta C.I., Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer. 69:1992;2496-2501.
63. Fisher B., Jeong J.H., Anderson S., Bryant J., Fisher E.R., Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N. Engl. J. Med. 347:2002;567-575.
64. Keshtgar M.R., Baum M. Axillary Dissection over the years. where to from here? World J. Surg. 25:2001;761-766.
65. Veronesi U., Paganelli G., Galimberti V.et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 349:1997;1864-1867.
66. Veronesi U., Galimberti V., Zurrida S.et al. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur. J. Cancer. 37:2001;454-458.
67. Clark R.M., Whelan T., Levine M.et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. an update. Ontario Clinical Oncology Group J. Natl. Cancer Inst. 88:1996;1659-1664.
68. Dalberg K., Johansson H., Johansson U., Rutqvist L.E. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group. Cancer. 82:1998;2204-2211.
69. Tamoxifen for early breast cancer. an overview of the randomised trials Lancet. 351:1998;1451-1467.
70. Fisher B., Costantino J., Redmond C.et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320:1989;479-484.
71. Kurtz J.M. Tamoxifen and breast conservation. do we still need radiotherapy? Cancer. 82:1998;2090-2092.
72. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H.J. Meeting highlights. International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer J. Clin. Oncol. 19:2001;3817-3827.
73. DelTurco M.R., Palli D., Cariddi A., Ciatto S., Pacini P., Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. JAMA. 271:1994;1593-1597.
74. Stotter A.T., McNeese M.D., Ames F.C., Oswald M.J., Ellerbroek N.A. Predicting the rate and extent of locoregional failure after breast conservation therapy for early breast cancer. Cancer. 64:1989;2217-2225.
75. Richards M.A., Westcombe A.M., Love S.B., Littlejohns P., Ramirez A.J. Influence of delay on survival in patients with breast cancer. a systematic review Lancet. 353:1999;1119-1126.
76. Sainsbury R., Johnston C., Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms. a retrospective analysis Lancet. 353:1999;1132-1135.
77. Fisher B., Anderson S., Fisher E.R.et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 338:1991;327-331.
78. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;71-85.
79. Riethmuller G., Holz E., Schlimok G.et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer. seven-year outcome of a multicenter randomized trial J. Clin. Oncol. 16:1998;1788-1794.
80. Rutqvist L.E., Cedermark B., Glas U.et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer. a summary of three randomized trials Int. J. Radiat. Oncol. Biol. Phys. 16:1989;629-639.
81. Diel I.J., Kaufmann M., Costa S.D.et al. Micrometastatic breast cancer cells in bone marrow at primary surgery. prognostic value in comparison with nodal status J. Natl. Cancer Inst. 88:1996;1652-1658.
82. Pantel K., von Knebel Doeberitz M., Izbicki J.R., Riethmuller G. Disseminated tumor cells. diagnosis, prognostic relevance, phenotyping and therapeutic strategies Chirurgia. 68:1997;1241-1250.
83. Olsen O., Gøtzsche P.C. Cochrane review on screening for breast cancer with mammography. Lancet. 358:2001;1340-1342.